Connect with us

Cannabis

Cannabis Europe conference to be held in Madrid in February

Cannabis Europe is at the forefront of the budding cannabis industry in Europe. With conferences all over the world lead by expert industry leaders, it is shaping the future of medical cannabis. Cannabis Europe is coming to Madrid, Spain, next month, and will focus on discussions on cannabis science, policy-making and business strategy with both European and international audiences.

Published

on

This picture show a cannabis plant.

The ‘Cannabis Europe’ Conference will be held in Madrid for the first time on February 10th, with several internationally renowned doctors and researchers to discuss cannabis for medical use. The conference will take place at the InterContinental Hotel.

A variety of subjects will be discussed at the background of European regulatory changes. Although there is strong social support for cannabis in Spain, the legal framework in the country is not yet defined.

Stay up to date with the latest news from cannabis and CBD sectors with CBD News mobile app.

Cannabis Europe started in 2018 with the intent to bring Europe to the forefront of the emerging cannabis market. The legalization of medical cannabis is a point of discussion in many European countries, and policymakers are calling for more research, to be able to work on proper legislation around the substance. Cannabis Europe is at the forefront of this movement.

Main objective of the Cannabis Europe conference

Cannabis Europe arrives in Spain in February 2020, one of Europe’s largest cannabis markets that has yet to legalize cannabis. According to the event organizers, the NOBL Group, who also own the international consultancy Prohibition Partners, the main objective of the conference is “to share knowledge and shape the future of medical cannabis in Spain and Europe.”

The event will bring together over 250 politicians, business leaders, and health professionals to discuss how to unlock Spain’s potential for access to medical cannabis. Several speakers will be present to share their vision and knowledge, from research to medicine, politics, and patients.

Bruno Maia, Neurologist at the “de São José Hospital”, and founding member of the OPCM – Portuguese Observatory of Medical Cannabis, will be one of the speakers of the event along with Janosch Kratz, MD, also a member of the Advisory Board of OPCM.

SEE ALSO  How to use word-of-mouth marketing to grow your business

Regulatory cannabis models in Spain

Deputy Piernicola Pedicini will give an overview of the different regulatory models in Spain and Europe. This will be followed by the President of the Spanish Federation of Pharmaceutical Companies, Luis de Palacio, who will be exploring how the infrastructure of a neighboring country can be channeled to support the development of Spanish medical cannabis.

Spain has been instrumental in the development of recreational cannabis culture in Europe. The first clubs were opened in 1991 and it’s estimated that there are more than 400 cannabis clubs throughout the country, including Catalonia, which placed Spain in the 3rd place in Europe for cannabis consumption, and 13th in the world.

Medical cannabis legalization in Spain

However, despite pioneering policies with regard to recreational consumption, Spain is still waiting behind the scenes for the legalization of medical cannabis, despite the fact that 84% of the population is in favor of its use. Spain, therefore, represents a strong commercial industry and has one of the most innovative biomedical sectors in the world, making it one of the most promising markets for cannabis in Europe, assuming a huge investment potential.

Cannabis Europe’ is one of Europe’s leading conference series on medical cannabis, with events around the world, that aims to be a platform for thought leadership, and an opportunity to connect influential leaders in science, politics and business.

__

(Featured image by Esteban Lopez via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in CANNA REPORTER, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.